{"id":56265,"date":"2026-02-04T21:09:01","date_gmt":"2026-02-04T13:09:01","guid":{"rendered":"https:\/\/flcube.com\/?p=56265"},"modified":"2026-02-04T21:09:02","modified_gmt":"2026-02-04T13:09:02","slug":"simcere-receives-40m-milestone-from-abbvie-for-trispecific-myeloma-drug","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56265","title":{"rendered":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Simcere Pharmaceutical Group Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG:\u202f2096<\/a>) announced it has received a <strong>USD\u202f40\u202fmillion near\u2011term milestone payment<\/strong> from <strong>AbbVie Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABBV:NYSE\">NYSE:\u202fABBV<\/a>) following positive clinical progress for <strong>SIM0500<\/strong>, a <strong>humanized trispecific antibody<\/strong> targeting <strong>GPRC5D, BCMA, and CD3<\/strong> for multiple myeloma. The payment was triggered under a licensing agreement signed in <strong>January\u202f2025<\/strong> that could total up to <strong>USD\u202f1.055\u202fbillion<\/strong> in milestones plus tiered royalties on ex\u2011Greater China sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Simcere Pharmaceutical Group Ltd (HKEX:\u202f2096)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>AbbVie Inc. (NYSE:\u202fABBV)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>SIM0500 (trispecific antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Multiple myeloma<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>Included in Jan\u202f2025 deal (amount undisclosed)<\/td><\/tr><tr><td><strong>Near\u2011Term Milestone<\/strong><\/td><td>USD\u202f40\u202fmillion (triggered by clinical progress)<\/td><\/tr><tr><td><strong>Total Potential<\/strong><\/td><td>Up to USD\u202f1.055\u202fbillion (option fees + milestones)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered on net sales outside Greater China<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Simcere retains Greater China rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-technology-platform\">Drug Profile &amp; Technology Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Trispecific antibody featuring:<\/li>\n\n\n\n<li><strong>Low affinity\/high target\u2011activating CD3 engaging arm<\/strong><\/li>\n\n\n\n<li><strong>Binding sites for GPRC5D<\/strong> (G\u2011Protein\u2011coupled receptor class 5 member D)<\/li>\n\n\n\n<li><strong>Binding sites for BCMA<\/strong> (B\u2011cell maturation antigen)<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Simcere\u2019s proprietary <strong>T\u2011cell engager polyspecific antibody technology<\/strong><\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Simultaneous targeting of two myeloma antigens enhances tumor cell killing while reducing off\u2011target effects<\/li>\n\n\n\n<li><strong>Clinical Status:<\/strong> Positive clinical progress triggered milestone; Phase\u202fIII trials underway<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-outlook\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Multiple Myeloma Market:<\/strong> Global market valued at <strong>$25\u202fbillion<\/strong> in 2025; bispecific\/trispecific antibodies represent <strong>fastest\u2011growing segment<\/strong><\/li>\n\n\n\n<li><strong>Trispecific Advantage:<\/strong> SIM0500 competes with <strong>bispecific antibodies (BCMA\/CD3)<\/strong> from <strong>J&amp;J (Teclistamab)<\/strong> and <strong>Pfizer (Elranatamab)<\/strong>; dual antigen binding may offer deeper and more durable responses<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate ex\u2011China market opportunity at <strong>$800\u202fmillion\u20131.2\u202fbillion<\/strong> : by 2030; SIM0500 could capture <strong>10\u201315%<\/strong> share<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Validation of Simcere\u2019s polyspecific platform attracts additional partnerships; AbbVie gains differentiated oncology asset to complement <strong>Imbruvica<\/strong> and <strong>Venclexta<\/strong><\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Additional milestones tied to Phase\u202fIII data and regulatory submissions; AbbVie to lead global development and commercialization<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, clinical development timelines, and revenue potential for SIM0500. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020301057_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020301057_c.\"><\/object><a id=\"wp-block-file--media-375f3e9f-ccb0-472a-8b25-64ce08f6b705\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020301057_c.pdf\">2026020301057_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020301057_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-375f3e9f-ccb0-472a-8b25-64ce08f6b705\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[234,1099,28,853,271],"class_list":["post-56265","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-abbvie","tag-hkg-2096","tag-multi-specific-antibodies","tag-nyse-abbv","tag-simcere-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56265\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56265\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T13:09:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T13:09:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug\",\"datePublished\":\"2026-02-04T13:09:01+00:00\",\"dateModified\":\"2026-02-04T13:09:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265\"},\"wordCount\":362,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"HKG: 2096\",\"Multi-specific antibodies\",\"NYSE: ABBV\",\"Simcere Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56265#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56265\",\"name\":\"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-04T13:09:01+00:00\",\"dateModified\":\"2026-02-04T13:09:02+00:00\",\"description\":\"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56265\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56265#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56265","og_locale":"en_US","og_type":"article","og_title":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug","og_description":"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.","og_url":"https:\/\/flcube.com\/?p=56265","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T13:09:01+00:00","article_modified_time":"2026-02-04T13:09:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56265#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56265"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug","datePublished":"2026-02-04T13:09:01+00:00","dateModified":"2026-02-04T13:09:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56265"},"wordCount":362,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","HKG: 2096","Multi-specific antibodies","NYSE: ABBV","Simcere Pharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56265#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56265","url":"https:\/\/flcube.com\/?p=56265","name":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-04T13:09:01+00:00","dateModified":"2026-02-04T13:09:02+00:00","description":"Simcere Pharmaceutical Group Ltd (HKG:\u202f2096) announced it has received a USD\u202f40\u202fmillion near\u2011term milestone payment from AbbVie Inc. (NYSE:\u202fABBV) following positive clinical progress for SIM0500, a humanized trispecific antibody targeting GPRC5D, BCMA, and CD3 for multiple myeloma. The payment was triggered under a licensing agreement signed in January\u202f2025 that could total up to USD\u202f1.055\u202fbillion in milestones plus tiered royalties on ex\u2011Greater China sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56265#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56265"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56265#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56265"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56265\/revisions"}],"predecessor-version":[{"id":56267,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56265\/revisions\/56267"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}